[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342489-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342489-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","emerging-roles-of-yes1-in-cancer-the-putative-target-in-drug-resistance","Emerging Roles of YES1 in Cancer - The Putative Target in Drug Resistance","","Src family kinases (SFKs) are non-receptor tyrosine kinases with proto-oncogenic functions, and YES1 is frequently amplified and overexpressed across human tumors, including lung, breast, ovarian, and skin cancers. YES1 promotes proliferation, survival, and invasiveness during tumor development. Evidence links YES1 expression and activation to resistance against chemotherapy and tyrosine kinase inhibitors. The study also examines how post-translational lipidation and nitrosylation shape YES1 activity, localization, and substrate binding, supporting its role in drug-resistance emergence.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/emerging-roles-of-yes1-in-cancer-the-putative-target-in-drug-resistance/342489/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/emerging-roles-of-yes1-in-cancer-the-putative-target-in-drug-resistance/342489.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-20","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does YES1 play in cancer development?","Question",{"text":63,"@type":64},"YES1 promotes cell proliferation, survival, and invasiveness during tumor development.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is YES1 linked to drug resistance?",{"text":68,"@type":64},"YES1 expression and activation correlate with resistance to chemotherapeutic drugs and tyrosine kinase inhibitors in human malignancies.",{"name":70,"@type":61,"acceptedAnswer":71},"Which post-translational modifications affect YES1 function?",{"text":72,"@type":64},"The article highlights lipidation and nitrosylation, which can modulate YES1 catalytic activity, subcellular localization, and substrate protein binding affinity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342489,1790111585,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Review  \nEmerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance  \nEunjin Kook 1, Kyung-Soo Chun 2 and Do-Hee Kim 1, *  \nCitation: Kook, E.; Chun, K.-S.; Kim, D.-H. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance. Int. J. Mol. Sci. 2024, 25, 1450. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25031450  \nAcademic Editor: Kathleen Pishas  \nReceived: 29 December 2023  \nRevised: 18 January 2024  \nAccepted: 22 January 2024  \nPublished: 25 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Chemistry, Kyonggi University, Suwon 16227, Republic of Korea; [world1024@kyonggi.ac.kr](world1024@kyonggi.ac.kr)  \n2 College of Pharmacy, Keimyung University, Daegu 42691, Republic of Korea; [chunks@kmu.ac.kr](chunks@kmu.ac.kr)  \n* Correspondence: [dohee@kyonggi.ac.kr](dohee@kyonggi.ac.kr)  \nAbstract: Src family kinases (SFKs) are non-receptor tyrosine kinases that are recognized as protooncogenic products. Among SFKs, YES1 is frequently amplified and overexpressed in a variety of human tumors, including lung, breast, ovarian, and skin cancers. YES1 plays a pivotal role in promoting cell proliferation, survival, and invasiveness during tumor development. Recent findings indicate that YES1 expression and activation are associated with resistance to chemotherapeutic drugs and tyrosine kinase inhibitors in human malignancies. YES1 undergoes post-translational modifications, such as lipidation and nitrosylation, which can modulate its catalytic activity, subcellular localization, and binding affinity for substrate proteins. Therefore, we investigated the diverse mechanisms governing YES1 activation and its impact on critical intracellular signal transduction pathways. We emphasized the function of YES1 as a potential mechanism contributing to the anticancer drug resistance emergence.  \nKeywords: Src family kinase; YES1; drug-resistance; cancer progression  \n1. Introduction  \nIn spite of substantial progress and enhancements in cancer treatments over recent years, the occurrence of resistance to cancer therapies is still a common observation in clinical settings. In addition, despite substantial progress in understanding the molecular mechanisms of resistance to targeted therapies based on tyrosine kinase inhibitors, and in developing more effective drugs, advanced cancers remain incurable. This is because tumors eventually develop resistance and relapse [1] . Consequently, numerous researchers are focused on identifying novel molecular biomarkers that could predict treatment responses and prevent tumor relapse. It has been reported that Src family kinases (SFKs) playa role in advancing oncogenesis and in conferring resistance to chemotherapy drugs as well as to molecular targeted therapies [2] .  \nSFKs are non-receptor tyrosine kinases that produce proto-oncogenes [3] . SFKs are recruited to the plasma membrane through interactions with transmembrane or adapter proteins, subsequently triggering intracellular signaling pathways that play roles in cell survival, adhesion, and motility [4] . At least nine SFKs are available in humans: Src, Yes, Lck, Fyn, Lyn, Hck, Blk, Fgr, and Yrk [4] . Within the SFK group, Yes, also known as YES1, shares the highest amino acid identity of 75% with Src, making it the closest paralog [5] . Srcand YES1 serve as scaffolds for protein–protein interactions. Altered expression levels and catalytic activities of these proteins have been observed in various human tumors, including lung, breast, ovarian, gastric, and colon cancer [6,7] . Several reports have previously demonstrated the involvement of YES1 expressi","cbCaic5I7HLeAqBA","https://ap.wps.com/l/cbCaic5I7HLeAqBA","pdf",725086,14,"English","# Abstract\n# Keywords\n# 1. Introduction\n# 2. Structure of YES1","[{\"question\":\"What role does YES1 play in cancer development?\",\"answer\":\"YES1 promotes cell proliferation, survival, and invasiveness during tumor development.\"},{\"question\":\"How is YES1 linked to drug resistance?\",\"answer\":\"YES1 expression and activation correlate with resistance to chemotherapeutic drugs and tyrosine kinase inhibitors in human malignancies.\"},{\"question\":\"Which post-translational modifications affect YES1 function?\",\"answer\":\"The article highlights lipidation and nitrosylation, which can modulate YES1 catalytic activity, subcellular localization, and substrate protein binding affinity.\"}]","Emerging Roles of YES1 in Cancer - The Putative Target in Drug Resistance | PDF",1790046817,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2681e73c99773c08998eff567ce8a1e.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3547171b9d235bcd4470b7ffc3294dd.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/616df40f0bc00ecbf336a2a4724a2b3c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d36c4fd7355c7678fbbbb81165afeaad.webp",980,1385]